ATE261444T1 - Pyrazolopyridine - Google Patents

Pyrazolopyridine

Info

Publication number: ATE261444T1
Authority: AT; Austria
Prior art keywords: 6alkyl; 6alkoxy; halogen; substituted; compounds
Prior art date: 1999-02-27

Application number

AT99968808T

Other languages

English (en)

Inventor

Ian Campbell

Paul Francis Lambeth

Alan Naylor

Neil Anthony Pegg

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-27

Filing date

1999-12-22

Publication date

2004-03-15

1999-02-27 Priority claimed from GBGB9904506.4A external-priority patent/GB9904506D0/en

1999-09-03 Priority claimed from GBGB9920904.1A external-priority patent/GB9920904D0/en

1999-12-22 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-03-15 Application granted granted Critical

2004-03-15 Publication of ATE261444T1 publication Critical patent/ATE261444T1/de

Links

150000005229 pyrazolopyridines Chemical class 0.000 title 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
229910052736 halogen Inorganic materials 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
125000001153 fluoro group Chemical group F* 0.000 abstract 2
150000002367 halogens Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)

AT99968808T 1999-02-27 1999-12-22 Pyrazolopyridine ATE261444T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9904506.4A GB9904506D0 (en)	1999-02-27	1999-02-27	Chemical compounds
GBGB9920904.1A GB9920904D0 (en)	1999-09-03	1999-09-03	Chemical compounds
PCT/EP1999/010263 WO2000052008A1 (en)	1999-02-27	1999-12-22	Pyrazolopyridines

Publications (1)

Publication Number	Publication Date
ATE261444T1 true ATE261444T1 (de)	2004-03-15

Family

ID=26315187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99968808T ATE261444T1 (de)	1999-02-27	1999-12-22	Pyrazolopyridine

Country Status (8)

Country	Link
US (1)	US6498166B1 (de)
EP (1)	EP1157025B1 (de)
JP (1)	JP2002538157A (de)
AT (1)	ATE261444T1 (de)
AU (1)	AU2661400A (de)
DE (1)	DE69915519T2 (de)
ES (1)	ES2216631T3 (de)
WO (1)	WO2000052008A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9930358D0 (en) *	1999-12-22	2000-02-09	Glaxo Group Ltd	Process for the preparation of chemical compounds
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021494D0 (en) *	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
ATE301653T1 (de)	2000-12-15	2005-08-15	Glaxo Group Ltd	Pyrazolopyridine
WO2002048148A2 (en)	2000-12-15	2002-06-20	Glaxo Group Limited	Pyrazolopyridine derivatives
DE60201074T2 (de)	2001-03-08	2005-09-15	Smithkline Beecham Corp.	Pyrazolopyridinderivate
US7012098B2 (en) *	2001-03-23	2006-03-14	Pharmacia Corporation	Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
EP1372643A1 (de)	2001-03-30	2004-01-02	Smithkline Beecham Corporation	Pyrazolopyridine, verfahren zu ihrer herstellung und verwendung als therapeutika
US7141569B2 (en)	2001-04-10	2006-11-28	Smithkline Beecham Corporation	Antiviral pyrazolopyridine compounds
ES2242028T3 (es)	2001-04-27	2005-11-01	Smithkline Beecham Corporation	Derivados de pirazolo(1,5-a)piridina.
GB0112802D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
HUP0400266A2 (hu)	2001-06-21	2004-08-30	Smithkline Beecham Corp.	Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
ATE364043T1 (de) *	2001-09-07	2007-06-15	Smithkline Beecham Corp	Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
WO2003031446A1 (en)	2001-10-05	2003-04-17	Smithkline Beecham Corporation	Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
GB0124934D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
AU2002357740A1 (en)	2001-12-11	2003-06-23	Smithkline Beecham Corporation	Pyrazolo-pyridine derivatives as antiherpes agents
BRPI0307351B8 (pt) *	2002-02-12	2021-05-25	Smithkline Beecham Corp	composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
AU2003258630A1 (en) *	2002-08-19	2004-03-11	Glaxo Group Limited	Pyrimidine derivatives as selective cox-2 inhibitors
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
JP2006504728A (ja)	2002-10-03	2006-02-09	スミスクラインビーチャムコーポレーション	ピラソロピリジン誘導体系治療用化合物
US20040220155A1 (en) *	2003-03-28	2004-11-04	Pharmacia Corporation	Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
GB0308186D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
ES2275218T3 (es)	2003-05-07	2007-06-01	Osteologix A/S	Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
WO2005009342A2 (en) *	2003-07-16	2005-02-03	Pharmacia Corporation	Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
GB0318814D0 (en) *	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0319037D0 (en) *	2003-08-13	2003-09-17	Glaxo Group Ltd	7-Azaindole Derivatives
US20050119262A1 (en) *	2003-08-21	2005-06-02	Pharmacia Corporation	Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) *	2003-09-03	2005-03-17	Pharmacia Corporation	Method of cox-2 selective inhibitor and nitric oxide-donating agent
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
CA2592442A1 (en)	2004-12-23	2006-06-29	Glaxo Group Limited	Pyridine compounds for the treatment of prostaglandin mediated diseases
US20070155738A1 (en)	2005-05-20	2007-07-05	Alantos Pharmaceuticals, Inc.	Heterobicyclic metalloprotease inhibitors
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
US7585875B2 (en)	2006-06-06	2009-09-08	Avigen, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
GB0704407D0 (en)	2007-03-07	2007-04-18	Glaxo Group Ltd	Compounds
US7943658B2 (en)	2007-07-23	2011-05-17	Bristol-Myers Squibb Company	Indole indane amide compounds useful as CB2 agonists and method
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
GB0813142D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
GB0813144D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en)	2009-08-27	2011-03-03	Glaxo Group Limited	Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en)	2010-01-15	2010-03-03	Glaxo Group Ltd	Novel compounds
GB201007789D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel Compound
GB201007791D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel compounds
JP5815029B2 (ja)	2010-07-09	2015-11-17	クオンベルゲンセプハルマセウトイカルスリミテッド	カルシウムチャネル遮断薬としてのテトラゾール化合物
JP6058556B2 (ja)	2011-01-19	2017-01-11	クオンベルゲンセプハルマセウトイカルスリミテッド	ＣａＶ２．２カルシウムチャンネルブロッカーとしてのピペラジン誘導体
GB201122113D0 (en)	2011-12-22	2012-02-01	Convergence Pharmaceuticals	Novel compounds
GB201417500D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417499D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417497D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
CN109906082A (zh)	2016-09-07	2019-06-18	塔夫茨大学信托人	使用免疫dash抑制剂和pge2拮抗剂的组合治疗
CA3209491A1 (en)	2021-03-15	2022-09-22	Saul Yedgar	Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5002941A (en)	1985-12-12	1991-03-26	Smithkline Beecham Corporation	Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en)	1987-06-15	1990-05-15	Fujisawa Pharmaceutical Company, Ltd.	Pharmaceutically useful pyrazolopyridines
US5155114A (en)	1989-01-23	1992-10-13	Fujisawa Pharmaceutical Company, Ltd.	Method of treatment using pyrazolopyridine compound
GB8901423D0 (en)	1989-01-23	1989-03-15	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
WO1991000092A1 (en)	1989-06-13	1991-01-10	Smithkline Beecham Corporation	Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU622330B2 (en)	1989-06-23	1992-04-02	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
AU8205991A (en)	1990-06-12	1992-01-07	Smithkline Beecham Corporation	Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en)	1990-07-18	1990-09-05	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
US5300478A (en)	1993-01-28	1994-04-05	Zeneca Limited	Substituted fused pyrazolo compounds
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
KR19980703559A (ko)	1995-04-04	1998-11-05	그레이엄브레레톤	이미다조［1,2-ａ］피리딘 유도체
US5700816A (en)	1995-06-12	1997-12-23	Isakson; Peter C.	Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
WO1996041626A1 (en)	1995-06-12	1996-12-27	G.D. Searle & Co.	Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
CA2224563A1 (en)	1995-06-12	1996-12-27	G.D. Searle & Co.	Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
ES2203985T3 (es)	1997-09-05	2004-04-16	Glaxo Group Limited	Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds

1999
- 1999-12-22 AT AT99968808T patent/ATE261444T1/de not_active IP Right Cessation
- 1999-12-22 DE DE69915519T patent/DE69915519T2/de not_active Expired - Lifetime
- 1999-12-22 ES ES99968808T patent/ES2216631T3/es not_active Expired - Lifetime
- 1999-12-22 EP EP99968808A patent/EP1157025B1/de not_active Expired - Lifetime
- 1999-12-22 WO PCT/EP1999/010263 patent/WO2000052008A1/en not_active Ceased
- 1999-12-22 US US09/890,925 patent/US6498166B1/en not_active Expired - Fee Related
- 1999-12-22 AU AU26614/00A patent/AU2661400A/en not_active Abandoned
- 1999-12-22 JP JP2000602234A patent/JP2002538157A/ja active Pending

Also Published As

Publication number	Publication date
AU2661400A (en)	2000-09-21
JP2002538157A (ja)	2002-11-12
EP1157025A1 (de)	2001-11-28
ES2216631T3 (es)	2004-10-16
US6498166B1 (en)	2002-12-24
DE69915519T2 (de)	2005-02-03
WO2000052008A1 (en)	2000-09-08
DE69915519D1 (en)	2004-04-15
EP1157025B1 (de)	2004-03-10

Legal Events

Date	Code	Title	Description
2004-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69915519D1 (en)	2004-04-15	Pyrazolopyridine
MY119689A (en)	2005-06-30	Pyrazolopyridine derivatives
YU11900A (sh)	2002-11-15	Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2)
TR199701105T1 (xx)	1998-02-21	�midazo (1,2-a)piridin t�revleri.
NO20022470D0 (no)	2002-05-24	Pyrimidinderivater
NO20044731L (no)	2004-12-30	Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
ATE302775T1 (de)	2005-09-15	Carbolinderivate
NO20055421L (no)	2005-12-20	Kinolinderivater som fosfodiestrase-inhibitorer
JO2311B1 (en)	2005-09-12	Alkyl inhibitors Ariel phosphodiesterase-4
SE9701304D0 (sv)	1997-04-09	Compounds
ATE332903T1 (de)	2006-08-15	Kondensierte pyridoindolderivate
DK1747220T3 (da)	2009-08-10	Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
DE60216745D1 (de)	2007-01-25	Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
ATE346067T1 (de)	2006-12-15	Carbolinderivate
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
MA27436A1 (fr)	2005-07-01	Derives de pyridine inhibiteurs de la cox-2
AP1564A (en)	2006-02-02	Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
DK1313740T3 (da)	2006-04-03	Prodrugs af imidazopyridinderivater
ATE325115T1 (de)	2006-06-15	Pyrimidinderivate als selektive cox-2-inhibitoren
MXPA03010583A (es)	2004-03-09	Derivados de pirimidina utiles como inhibidores de cox-2 selectivos.
MXPA03004023A (es)	2004-02-12	Compuestos quimicos.
GB0319037D0 (en)	2003-09-17	7-Azaindole Derivatives
ATE274515T1 (de)	2004-09-15	Pyrazolopyridinderivate
ATE297926T1 (de)	2005-07-15	Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
SE9701396D0 (sv)	1997-04-15	Compounds